For a better user experience please update your browser or use Chrome or Firefox browser.
Uslužni programi
Publication detail
HomeStudy of the mapping of pharmaceutical manufacturers in Korea for the Health Emergency Preparedness and Response Authority (HERA)
Metapodaci o publikaciji
This analytical study provides a comprehensive overview of the pharmaceutical manufacturing landscape in South Korea, covering generics, vaccines, diagnostics, APIs, and PPE. The data is drawn from a total of 653 registered Korean pharmaceutical companies, with a focus on major players distinguished by their revenue. Detailed company profiles and product listings are available in Annexes. South Korea's pharmaceutical market, which grew by 16.7% in 2022 to USD 22.4 billion, is a robust and expanding sector. This growth reflects an increase in both imports and exports, with domestic production standing at USD 21.7 billion, 37.3% of which is exported. Korea is a notable player in the global pharmaceutical industry, ranking as the world’s fifth-largest clinical trial market and a leader in biosimilars. Since 2019, the country has been included on the EU Whitelist, underscoring its growing international influence. The Korean pharmaceutical sector is characterized by world-class biopharmaceutical production facilities, driven by government-led initiatives, and a burgeoning presence in overseas investments.
- Objavljeno:
- Teme: Azija , Farmaceutska i kozmetička industrija
- Predmet: farmaceutska industrija , industrijski proces proizvodnje , istraživanje i razvoj , kliničko ispitivanje , Koreja (Južna) , lanac opskrbe , propisi o lijekovima , trgovinski promet , ulaganje
|
PDF
|
|||
| ISSN | ISBN 978-92-9413-008-2 | DOI 10.2929/8773674 | Kataloški broj LN-01-24-001-EN-N |
- Released on EU publications website:
Preglednik dokumenata
Note:
Publikacija se ne može prikazati u pregledniku dokumenata. Otvori internetsku verziju
Dostupno na: Preuzmi i odaberi jezik